WS #13331
Holding: newest synthesis is 100d old
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.
AstraZeneca-Bristol Myers merger rejected by investors
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.